A Trial to Compare the Efficacy and Safety of Once-weekly Lonapegsomatropin With Placebo and a Daily Somatropin Product in Adults With Growth Hormone Deficiency

NCT ID: NCT04615273

Last Updated: 2025-01-15

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: PHASE3
• Total Enrollment: 264 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2020-12-03
• Study Completion Date: 2023-12-01

Brief Summary

A 38-week dosing trial of lonapegsomatropin, a long-acting growth hormone product, administered once-a-week versus placebo-control. A daily somatropin product arm is also included to assist clinical judgement on the trial results. A total of 264 adults (males and females) with growth hormone deficiency were included. Randomization occurred in a 1:1:1 ratio (lonapegsomatropin: placebo: daily somatropin product). This is a global trial conducted in, but not limited to, the United States, Europe, and Asia.

Conditions

Growth Hormone Deficiency; Endocrine System Diseases; Hormone Deficiency

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: TREATMENT
• Blinding Strategy: DOUBLE

Study Groups

Lonapegsomatropin

Lonapegsomatropin administered once-weekly by subcutaneous injection.

Group Type: EXPERIMENTAL

Lonapegsomatropin

Intervention Type: DRUG

Due to the different human growth hormone (hGH) dose requirements, depending on participant's age and concomitant use of oral estrogen, this trial has 3 dosing groups per arm, followed by gradual increasing dose titration to a target maintenance dose.

Placebo

Placebo for Lonapegsomatropin administered once-weekly by subcutaneous injection.

Group Type: PLACEBO_COMPARATOR

Placebo

Intervention Type: OTHER

The placebo for lonapegsomatropin drug product contained the same excipients as lonapegsomatropin drug product but does not contain lonapegsomatropin itself. The placebo solution was administered by subcutaneous (SC) injection via syringe and needle. Due to the different hGH dose requirements, depending on participant's age and concomitant use of oral estrogen, this trial has 3 dosing groups and the placebo received the same dose volume as if they were randomized to once-weekly lonapegsomatropin.

Somatropin

Somatropin administered once-daily by subcutaneous injection.

Group Type: ACTIVE_COMPARATOR

Somatropin

Intervention Type: DRUG

Somatropin solution is provided in a pre-filled pen intended for daily subcutaneous injection. Due to the different hGH dose requirements, depending on participant's age and concomitant use of oral estrogen, this trial has 3 dosing groups per arm, followed by gradual increasing dose titration to a target maintenance dose.

Interventions

Lonapegsomatropin

Due to the different human growth hormone (hGH) dose requirements, depending on participant's age and concomitant use of oral estrogen, this trial has 3 dosing groups per arm, followed by gradual increasing dose titration to a target maintenance dose.

Intervention Type: DRUG

Placebo

The placebo for lonapegsomatropin drug product contained the same excipients as lonapegsomatropin drug product but does not contain lonapegsomatropin itself. The placebo solution was administered by subcutaneous (SC) injection via syringe and needle. Due to the different hGH dose requirements, depending on participant's age and concomitant use of oral estrogen, this trial has 3 dosing groups and the placebo received the same dose volume as if they were randomized to once-weekly lonapegsomatropin.

Intervention Type: OTHER

Somatropin

Somatropin solution is provided in a pre-filled pen intended for daily subcutaneous injection. Due to the different hGH dose requirements, depending on participant's age and concomitant use of oral estrogen, this trial has 3 dosing groups per arm, followed by gradual increasing dose titration to a target maintenance dose.

Intervention Type: DRUG

Eligibility Criteria

Inclusion Criteria

1. Age between 23 and 80 years, inclusive, at screening.

2. Adult Growth Hormone Deficiency (AGHD) Diagnosis Criteria

• For adult-onset AGHD: documented history of structural hypothalamic-pituitary disease, hypothalamic-pituitary surgery, cranial irradiation, 1-4 non-GH pituitary hormone deficiencies, a proven genetic cause of GHD, or traumatic brain injury (TBI).
• Participants with childhood-onset GHD must have had GH axis re-assessed at final height.
• In participants with TBI as a cause of GHD, GHD must be confirmed by GH -stimulation testing performed at least 12 months after the injury.

A. For all countries except Japan: participants must have satisfied at least one of the following criteria:

1. Insulin tolerance test: peak growth hormone (GH) <=5 ng/mL

2. Glucagon stimulation test according to body mass index (BMI)

• i. BMI <=30 kg/m^2: peak GH <=3 ng/mL
• ii. BMI >30 kg/m^2: peak GH <=1 ng/mL

3. Three or four pituitary axis deficiencies (i.e., adrenal, thyroid, gonadal, and/or vasopressin; not including GH) with insulin-like growth factor-1 standard deviation score (IGF-1 SDS) <= -2.0 at screening

4. Macimorelin test: peak GH <=2.8 ng/mL

5. Growth hormone releasing hormone (GHRH) + arginine test according to BMI:

• i. BMI <25 kg/m^2, peak GH <11 ng/mL
• ii. BMI >=25-<=30 kg/m^2, peak GH <8 ng/mL
• iii. BMI >30 kg/m^2, peak GH <4 ng/mL

B. For Japan only: Participants with AGHD and deficiency of at least one non-GH pituitary hormones need to satisfy one of the following GH stimulation tests. Participants with GHD without additional non-GH pituitary hormone deficiencies with or without and evidence of intracranial structure disorder need to satisfy at least 2 of the following stimulation tests:

1. Insulin tolerance test: peak GH <=1.8 ng/mL

2. Glucagon test: peak GH <=1.8 ng/mL

3. Growth Hormone Releasing Peptide-2 (GHRP-2) tolerance test: peak GH <=9 ng/mL

3. IGF-1 SDS <= -1.0 at screening as measured by central laboratory.

4. hGH treatment naïve or no exposure to hGH therapy or GH secretagogue for at least 12 months prior to screening.

5. For participants on hormone replacement therapies for any hormone deficiencies other than GH (e.g., adrenal, thyroid, estrogen, testosterone) must be on adequate and stable doses for >=6 weeks prior to and throughout screening.

6. For participants not on glucocorticoid replacement therapy, documentation of adequate adrenal function at screening defined as: morning (6:00-10:00 AM) serum cortisol >15.0 mcg/dL (measured at central laboratory) and/or adrenocorticotropic hormone (ACTH) stimulation test or insulin tolerance test with serum cortisol >18.0 mcg/dL at or within 90 days prior to screening.

7. For males not on testosterone replacement therapy: morning (6:00 - 10:00AM) total testosterone within normal limits for age.

8. On a stable diet and exercise regime at screening with no intention to modify diet or exercise pattern during the trial, i.e., no weight reduction program intended during the trial or within the last 90 days prior to or through screening.

9. No plans to undergo bariatric surgery during the trial.

10. Fundoscopy at screening without signs/symptoms of intracranial hypertension or diabetic retinopathy above stage 2 / moderate or above or any other retinal disease contraindicated to growth hormone therapy. For participants with a diagnosis of diabetes mellitus at screening, this must be documented with a fundus photograph.

11. Able and willing to provide a written informed consent and authorization for protected health information (PHI) disclosure in accordance with Good Clinical Practice (GCP).

12. Serum free thyroxine (fT4) in the normal range at screening as measured by central laboratory.

Exclusion Criteria

1. Known Prader-Willi Syndrome and/or other genetic diseases that may have an impact on an endpoint.

2. Diabetes mellitus at screening if any of the following criteria are met:

1. Poorly controlled diabetes, defined as HbA1c >7.5% at screening.

2. Diabetes mellitus (defined as HbA1c >=6.5% and/or fasting plasma glucose >=126 mg/dL and/or plasma glucose >=200 mg/dL two hours after oral glucose tolerance test) diagnosed <26 weeks prior to screening

3. Change in diabetes regimen (includes dose adjustment) within <90 days prior and throughout screening

4. Use of any diabetes drugs other than metformin and/or dipeptidyl peptidase-4 (DPP-4) inhibitors for a cumulative duration of greater than 4 weeks within 12 months prior to screening

5. Diabetes-related complications at screening (i.e., nephropathy as judged by the investigator, neuropathy requiring pharmacological treatment, retinopathy stage 2/moderate and above within 90 days prior to screening or during screening)

3. Active malignant disease or history of malignancy. Exceptions to this exclusion criterion:

1. Resection of in situ carcinoma of the cervix uteri

2. Complete eradication of squamous cell or basal cell carcinoma of the skin

3. Participants with GHD attributed to treatment of intracranial malignant tumors or leukemia, provided that a recurrence-free survival period of at least 5 years prior to screening is documented in the participant's file (based on a Magnetic Resonance Imaging (MRI) result for intracranial malignant tumors)

4. Evidence of growth of pituitary adenoma or other benign intracranial tumor within the last 12 months before screening.

5. Participants with acromegaly without remission / with documented remission less than 24 months prior to screening.

6. Participants with Cushing's disease without remission / with documented remission less than 24 months prior to screening.

7. Participants with prior cranial irradiation or hypothalamic-pituitary surgery: the procedure was to take place less than 12 months prior to screening.

8. Estimated glomerular filtration rate (eGFR) <60 mL/min/1.73m^2 determined based on Modification of Diet in Renal Disease (MDRD) equation.

9. Hepatic transaminases (i.e., aspartate aminotransferase [AST] or alanine aminotransferase [ALT]) >3 times the upper limit of normal.

10. Heart failure New York Heart Association (NYHA) class 3 or greater (NYHA 1994).

11. Q-T interval, corrected by Fridericia's method (QTcF) >= 451 milliseconds on 12-lead electrocardiogram (ECG) at screening.

12. Poorly controlled hypertension, defined as supine systolic blood pressure >159 mmHg and/or supine diastolic blood pressure >95 mmHg at screening.

13. Cerebrovascular accident within 5 years prior to screening.

14. Anabolic steroids (other than gonadal steroid replacement therapy) or oral/intravenous/intramuscular corticosteroids within 90 days prior to or throughout screening.

15. Currently using or have used within 26 weeks prior to screening any weight-loss or appetite-suppressive medications including orlistat, zonisamide, lorcaserin, bupropion, topiramate, sibutramine, stimulants, glucagon-like peptide 1 (GLP-1) receptor agonists, sodium-dependent glucose cotransporters (SGLT-2) inhibitors or medications that affects IGF-1 or GH measurements including cabergoline at doses above 0.5 mg weekly or bromocriptine at doses above 20 mg weekly.

16. Known history of hypersensitivity and/or idiosyncrasy to any of the test compounds (somatropin) or excipients employed in this trial.

17. Known history of neutralizing anti-hGH antibodies.

18. Inability to undergo scanning by dual-energy x-ray absorptiometry (DXA) or a non-interpretable DXA scan at screening.

19. Female who is pregnant, breast-feeding or intends to become pregnant or is of childbearing potential (i.e., fertile, following menarche and until becoming post-menopausal unless permanently sterile) and not using adequate contraceptive methods.

20. Male participants must use a condom, or his female partner of childbearing potential must use an effective form of contraception as described above, from the beginning of screening to the last trial visit.

21. Known substance abuse or known (or previous) eating disorders, including anorexia nervosa, bulimia and severe gastrointestinal disease affecting normal eating (as judged by the investigator).

22. Any disease or condition that, in the judgement of the investigator, may make the subject unlikely to comply with the requirements of the trial or any condition that presents undue risk from the investigational product or procedures.

23. Participation in another interventional clinical trial involving an investigational compound within 26 weeks prior to screening or in parallel to this trial.

24. Currently using or have used within the last 3 days prior to screening: biotin >0.03 mg/day from supplements

25. Known history of positive results of tests for human immunodeficiency virus (HIV) antibodies or hepatitis B and/or C (exceptions if vaccinated towards Hepatitis B virus and Hepatitis C virus).

26. Any of the following: acute critical illness, and complications following open heart surgery, abdominal surgery, multiple accidental traumas, acute respiratory failure, or similar conditions within 180 days prior to screening.

• Minimum Eligible Age: 23 Years
• Maximum Eligible Age: 80 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Ascendis Pharma Endocrinology Division A/S

INDUSTRY

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Locations

Ascendis Pharma Investigational Site

Birmingham, Alabama, United States

Ascendis Pharma Investigational Site

Phoenix, Arizona, United States

Ascendis Pharma Investigational Site

Fresno, California, United States

Ascendis Pharma Investigational Site

Los Angeles, California, United States

Ascendis Pharma Investigational Site

Los Angeles, California, United States

Ascendis Pharma Investigational Site

Palo Alto, California, United States

Ascendis Pharma Investigational Site

Torrance, California, United States

Ascendis Pharma Investigational Site

Chicago, Illinois, United States

Ascendis Pharma Investigational Site

Indianapolis, Indiana, United States

Ascendis Pharma Investigational Site

Boston, Massachusetts, United States

Ascendis Pharma Investigational Site

Dearborn, Michigan, United States

Ascendis Pharma Investigational Site

Rochester, Minnesota, United States

Ascendis Pharma Investigational Site

St Louis, Missouri, United States

Ascendis Pharma Investigational Site

Las Vegas, Nevada, United States

Ascendis Pharma Investigational Site

Reno, Nevada, United States

Ascendis Pharma Investigational Site

New York, New York, United States

Ascendis Pharma Investigational Site

New York, New York, United States

Ascendis Pharma Investigational Site

Morehead City, North Carolina, United States

Ascendis Pharma Investigational Site

Portland, Oregon, United States

Ascendis Pharma Investigational Site

Pittsburgh, Pennsylvania, United States

Ascendis Pharma Investigational Site

Dallas, Texas, United States

Ascendis Pharma Investigational Site

San Antonio, Texas, United States

Ascendis Pharma Investigational Site

Seattle, Washington, United States

Ascendis Pharma Investigational Site

Yerevan, , Armenia

Ascendis Pharma Investigational Site

Saint Leonards, New South Wales, Australia

Ascendis Pharma Investigational Site

Sydney, New South Wales, Australia

Ascendis Pharma Investigational Site

Box Hill, Victoria, Australia

Ascendis Pharma Investigational Site

Fitzroy, Victoria, Australia

Ascendis Pharma Investigational Site

Parkville, Victoria, Australia

Ascendis Pharma Investigational Site

Perth, Western Australia, Australia

Ascendis Pharma Investigational Site

Vancouver, British Columbia, Canada

Ascendis Pharma Investigational Site

Halifax, Nova Scotia, Canada

Ascendis Pharma Investigational Site

Copenhagen, , Denmark

Ascendis Pharma Investigational Site

Lyon, , France

Ascendis Pharma Investigational Site

Marseille, , France

Ascendis Pharma Investigational Site

Nantes, , France

Ascendis Pharma Investigational Site

Paris, , France

Ascendis Pharma Investigational Site

Tbilisi, , Georgia

Ascendis Pharma Investigational Site

Tbilisi, , Georgia

Ascendis Pharma Investigational Site

München, Bavaria, Germany

Ascendis Pharma Investigational Site

Athens, Attica, Greece

Ascendis Pharma Investigational Site

Athens, Attica, Greece

Ascendis Pharma Investigational Site

Thessaloniki, Central Macedonia, Greece

Ascendis Pharma Investigational Site

Thessaloniki, , Greece

Ascendis Pharma Investigational Site

Beersheba, , Israel

Ascendis Pharma Investigational Site

Haifa, , Israel

Ascendis Pharma Investigational Site

Petah Tikva, , Israel

Ascendis Pharma Investigational Site

Tel Aviv, , Israel

Ascendis Pharma Investigational Site

Genova, , Italy

Ascendis Pharma Investigational Site

Rome, , Italy

Ascendis Pharma Investigational Site

Rome, , Italy

Ascendis Pharma Investigational Site

Rozzano, , Italy

Ascendis Pharma Investigational Site

Kobe, Hyōgo, Japan

Ascendis Pharma Investigational Site

Kawasaki, Kanagawa, Japan

Ascendis Pharma Investigational Site

Yokohama, Kanagawa, Japan

Ascendis Pharma Investigational Site

Yokohama, Kanagawa, Japan

Ascendis Pharma Investigational Site

Matsumoto, Nagano, Japan

Ascendis Pharma Investigational Site

Kashihara, Nara, Japan

Ascendis Pharma Investigational Site

Ishikawa, Okinawa, Japan

Ascendis Pharma Investigational Site

Suita, Osaka, Japan

Ascendis Pharma Investigational Site

Chiba, , Japan

Ascendis Pharma Investigational Site

Fukuoka, , Japan

Ascendis Pharma Investigational Site

Kagoshima, , Japan

Ascendis Pharma Investigational Site

Kawasaki, , Japan

Ascendis Pharma Investigational Site

Nagakute, , Japan

Ascendis Pharma Investigational Site

Okayama, , Japan

Ascendis Pharma Investigational Site

Osaka, , Japan

Ascendis Pharma Investigational Site

Tokyo, , Japan

Ascendis Pharma Investigational Site

Yamagata, , Japan

Ascendis Pharma Investigational Site

George Town, , Malaysia

Ascendis Pharma Investigational Site

Kota Bharu, , Malaysia

Ascendis Pharma Investigational Site

Malacca, , Malaysia

Ascendis Pharma Investigational Site

Putrajaya, , Malaysia

Ascendis Pharma Investigational Site

Leiden, , Netherlands

Ascendis Pharma Investigational Site

Palmerston North, Manawatu-Wanganui, New Zealand

Ascendis Pharma Investigational Site

Wellington, , New Zealand

Ascendis Pharma Investigational Site

Krakow, , Poland

Ascendis Pharma Investigational Site

Lodz, , Poland

Ascendis Pharma Investigational Site

Poznan, , Poland

Ascendis Pharma Investigational Site

Warsaw, , Poland

Ascendis Pharma Investigational Site

Wroclaw, , Poland

Ascendis Pharma Investigational Site

Bucharest, , Romania

Ascendis Pharma Investigational Site

Iași, , Romania

Ascendis Pharma Investigational Site

Timișoara, , Romania

Ascendis Pharma Investigational Site

Belgrade, , Serbia

Ascendis Pharma Investigational Site

Kragujevac, , Serbia

Ascendis Pharma Investigational Site

Bratislava, , Slovakia

Ascendis Pharma Investigational Site

Ľubochňa, , Slovakia

Ascendis Pharma Investigational Site

Seoul, , South Korea

Ascendis Pharma Investigational Site

Seoul, , South Korea

Ascendis Pharma Investigational Site

Seoul, , South Korea

Ascendis Pharma Investigational Site

Suwon, , South Korea

Ascendis Pharma Investigational Site

Alicante, , Spain

Ascendis Pharma Investigational Site

Barcelona, , Spain

Ascendis Pharma Investigational Site

Barcelona, , Spain

Ascendis Pharma Investigational Site

Madrid, , Spain

Ascendis Pharma Investigational Site

Santiago de Compostela, , Spain

Ascendis Pharma Investigational Site

Seville, , Spain

Ascendis Pharma Investigational Site

Ankara, , Turkey (Türkiye)

Ascendis Pharma Investigational Site

Antalya, , Turkey (Türkiye)

Ascendis Pharma Investigational Site

Aydin, , Turkey (Türkiye)

Ascendis Pharma Investigational Site

Izmir, , Turkey (Türkiye)

Ascendis Pharma Investigational Site

İzmit, , Turkey (Türkiye)

Ascendis Pharma Investigational Site

Kayseri, , Turkey (Türkiye)

Ascendis Pharma Investigational Site

Ivano-Frankivsk, , Ukraine

Ascendis Pharma Investigational Site

Kharkiv, , Ukraine

Ascendis Pharma Investigational Site

Kyiv, , Ukraine

Ascendis Pharma Investigational Site

Kyiv, , Ukraine

Ascendis Pharma Investigational Site

Kyiv, , Ukraine

Ascendis Pharma Investigational Site

Vinnytsia, , Ukraine

Ascendis Pharma Investigational Site

Cardiff, , United Kingdom

Ascendis Pharma Investigational Site

Coventry, , United Kingdom

Ascendis Pharma Investigational Site

Leeds, , United Kingdom

Countries

United States; Armenia; Australia; Canada; Denmark; France; Georgia; Germany; Greece; Israel; Italy; Japan; Malaysia; Netherlands; New Zealand; Poland; Romania; Serbia; Slovakia; South Korea; Spain; Turkey (Türkiye); Ukraine; United Kingdom

Provided Documents

Document Type: Study Protocol

View Document

Document Type: Statistical Analysis Plan

View Document

Other Identifiers

2020-000929-42

Identifier Type: EUDRACT_NUMBER

Identifier Source: secondary_id

TCH-306

Identifier Type: -

Identifier Source: org_study_id